RNA Therapeutics

RNA Therapeutics is a private U.S. biotechnology company focused on mRNA-based delivery of therapeutic proteins and vaccines. The company positions itself as a bench-to-bedside developer of advanced mRNA therapeutic solutions and highlights programs spanning infectious disease vaccines and antibodies, cancer vaccines and therapeutic antibodies, rare disease therapeutics, and autoimmune disease therapeutics. Its disclosed lead program is RNAT-89, an mRNA lipid nanoparticle formulation designed to express darbepoetin for anemia indications, and the company announced in August 2024 that it had received FDA pre-IND feedback on that asset. RNA Therapeutics emphasizes the potential of ribosomal in vivo production of biologic medicines as a lower-cost alternative to traditional recombinant manufacturing.